Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 239 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Buffered Saline Clear all

Conditions: Scoliosis Idiopathic, Scoliosis;Congenital
Interventions: Normosol-R, buffered 2% hypertonic saline; Drug
Lead sponsor: Joseph D. Tobias; Other
Eligibility: 10 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Alopecia
Interventions: Hair Stimulating Complex (HSC), Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 40 Years to 70 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Graft Vs Host Disease
Interventions: PRO 140, Placebo; Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 8
States / cities: Miami, Florida • Maywood, Illinois • Detroit, Michigan + 5 more

Conditions: Carcinoma, Squamous Cell of Head and Neck
Interventions: Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT); Drug · Radiation
Lead sponsor: Julie E. Bauman, MD, MPH; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Wrinkles
Interventions: Elevess; Device
Lead sponsor: Anika Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Los Angeles, California • Boca Raton, Florida • Coral Gables, Florida + 6 more

Conditions: Influenza
Interventions: VCL-IPT1, VCL-IPM1, PBS; Biological
Lead sponsor: Vical; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2007
U.S. locations: 3
States / cities: San Diego, California • Baltimore, Maryland • Stony Brook, New York

Conditions: Influenza, Human
Interventions: D-SUIV cH8/1N1+AS03, D-SUIV cH5/1N1+AS03, D-SUIV cH11/1N1+AS03, D-SUIV cH8/1N1+AS01, D-SUIV cH5/1N1+AS01, D-SUIV cH11/1N1+AS01, D-SUIV cH8/1N1, D-SUIV cH5/1N1, D-SUIV cH11/1N1, Placebo, Fluarix Quadrivalent; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 470 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: South Miami, Florida • Wichita, Kansas • Rochester, New York + 2 more

Conditions: Anterior Uveitis
Interventions: 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops; Drug
Lead sponsor: Eyegate Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years to 85 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 39
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more

Conditions: Mumps
Interventions: CVM150, CVM26, Placebo; Biological · Other
Lead sponsor: CyanVac LLC; Industry
Eligibility: 18 Years to 29 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Rochester, New York • Cincinnati, Ohio • North Charleston, South Carolina

Conditions: Shigellosis
Interventions: Shigella4V2, Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Baltimore, Maryland • Cincinnati, Ohio

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic acid injection, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: Hantaan Virus
Interventions: Hantaan Vaccine:, Puumala Vaccine, Hantaan/Puumala Vaccine; Biological
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 49 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Silver Spring, Maryland

Conditions: Anemia, Sickle Cell
Interventions: Rivipansel, Placebo; Drug · Other
Lead sponsor: Biossil Inc.; Industry
Eligibility: 6 Years and older
Enrollment: 345 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 126
States / cities: Mobile, Alabama • Little Rock, Arkansas • Oakland, California + 40 more

Conditions: Intraocular Lens Replacement
Interventions: OMS302, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 13
States / cities: Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more

Conditions: Influenza, Vaccine
Interventions: cH8/1N1 LAIV, AS03-adjuvanted cH5/1N1 IIV, cH5/1N1 IIV, AS03-adjuvanted cH8/1N1 IIV, Normal saline, Phosphate buffered saline (PBS); Biological
Lead sponsor: PATH; Other
Eligibility: 18 Years to 39 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Durham, North Carolina • Cincinnati, Ohio

Conditions: Graft Versus Host Disease, Ocular Surface Disease, oGVHD, Ocular Graft vs Host Disease, Brimonidine Tartrate, Lubricant Eye Drops, Ophthalmic Solutions, Graft vs Host Disease
Interventions: Brimonidine Tartrate, Placebos; Drug
Lead sponsor: Ocugen; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Phoenix, Arizona • Palo Alto, California • Atlanta, Georgia + 10 more

Conditions: Male Pattern Hair Loss
Interventions: HST 001, Phosphate Buffered Saline; Biological · Other
Lead sponsor: Histogen; Industry
Eligibility: 25 Years to 55 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Encinitas, California

Conditions: Huntington's Disease
Interventions: VX15/2503, Placebo; Drug
Lead sponsor: Vaccinex Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 24 more

Conditions: Avian Influenza, Influenza, Influenza Immunisation
Interventions: AS03, Inactivated influenza H7N9 vaccine, Influenza Virus Quadrivalent Inactivated Vaccine, Phosphate Buffered Saline (PBS) diluent; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 64 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Birmingham, Alabama • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Covid19, SARS-CoV Infection
Interventions: Shampoo and saline, Saline and Listerine, Shampoo and Listerine, Saline and Saline; Combination Product
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • State College, Pennsylvania

Conditions: Healthy Adult Volunteers
Interventions: NB-1008, Control; Biological · Other
Lead sponsor: NanoBio Corporation; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 199 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Typhoid VI Polysaccharide Vaccine Injectable Solution, Saline Placebo (0.5mL injection); Biological · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Chikungunya Virus Infection
Interventions: VLA1553, Placebo; Biological
Lead sponsor: Valneva Austria GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 4,128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 44
States / cities: Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more

Conditions: Chronic Kidney Disease, Stage 4, Chronic Kidney Disease, Stage 5, EBV-Related Lymphoproliferative Disorder, EBV-Related Malignant Neoplasm, Post-Transplant Lymphoproliferative Disorder
Interventions: Biospecimen Collection, Dulbecco''s Phosphate-Buffered Saline, Peptide Vaccine, QS21; Procedure · Drug · Biological
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Hypertonic Saline in Posterior Spinal Fusion

Safety and Tolerability of Hair Stimulating Complex (HSC) in Female Pattern Hair Loss

A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Safety Study of Cosmetic Tissue Augmentation in People of Color

Pandemic Influenza Plasmid DNA Vaccines (Needle)

A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults

A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Puumala Virus DNA Vaccine

Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine

Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Safety and Efficacy of HST 001 in Male Pattern Hair Loss

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial

Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008

Inflammatory Challenge and Fear

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants